Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer
Journal of Clinical Oncology · 01.09.2023 · 41 (25) · 4107-4117
DOI: 10.1200/jco.22.02887 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Oncology, erschienen am 01.09.2023. Verfasst von Peter H O'Donnell und 24 weiteren Autor:innen. Beteiligte Einrichtung: University of Chicago, Chicago, IL. Hauptthemen laut MEDLINE: Cisplatin, Carcinoma, Transitional Cell. Die Arbeit wurde bisher 182-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NCATS NIH HHS.
Abstract (Originalsprache)
PURPOSE Patients with locally advanced or metastatic urothelial cancer (la/mUC) who are ineligible for cisplatin-based therapy have limited first-line (1L) treatment options and significant need for improved therapies. Enfortumab vedotin (EV) and pembrolizumab (Pembro) individually have shown a survival benefit in urothelial cancer in second-line + la/mUC settings. Here, we present data from the pivotal trial of EV plus Pembro (EV + Pembro) in the 1L setting. PATIENTS AND METHODS In Cohort K of the EV-103 phase Ib/II study, cisplatin-ineligible patients with previously untreated la/mUC were randomly assigned 1:1 to receive EV as monotherapy or in combination with Pembro. The primary end point was confirmed objective response rate (cORR) per blinded independent central review. Secondary end points included duration of response (DOR) and safety. There were no formal statistical comparisons between treatment arms. RESULTS The cORR was 64.5% (95% CI, 52.7 to 75.1) and 45.2% (95% CI, 33.5 to 57.3) for patients treated with EV + Pembro (N = 76) and EV monotherapy (N = 73), respectively. The median DOR was not reached for the combination and was 13.2 months for monotherapy; 65.4% and 56.3% of patients who responded to the combination and monotherapy, respectively, maintained a response at 12 months. The most common grade 3 or higher treatment-related adverse events (TRAEs) in patients treated with the combination were maculopapular rash (17.1%), fatigue (9.2%), and neutropenia (9.2%). EV TRAEs of special interest (any grade) in the combination arm included skin reactions (67.1%) and peripheral neuropathy (60.5%). CONCLUSION EV + Pembro showed a high cORR with durable responses as 1L treatment in cisplatin-ineligible patients with la/mUC. Patients who received EV monotherapy had a response and safety profile consistent with previous studies. Adverse events for EV + Pembro were manageable, with no new safety signals observed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- University of Chicago, Chicago, IL.
- University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC.
- Yale Cancer Center, New Haven, CT.
- Duke Cancer Institute, Duke University, Durham, NC.
- University of Colorado Comprehensive Cancer Center, Aurora, CO.
- University of California at Irvine, Irvine, CA.
ORCID-Profile: Peter H O'Donnell, Matthew I Milowsky, Daniel P Petrylak, Christopher J Hoimes, Thomas W Flaig, Nataliya Mar, Terence W Friedlander, Rana R McKay, Mehmet A Bilen, Earle F Burgess, Chethan Ramamurthy, Saby George, Daniel M Geynisman, Sergio Bracarda, Anne-Sophie Carret, Jonathan E Rosenberg
Förderung
- NCI NIH HHS
- NCATS NIH HHS
Zitieren
APA
O'Donnell, P. H., Milowsky, M. I., Petrylak, D. P., Hoimes, C. J., Flaig, T. W., Mar, N., Moon, H. H., Friedlander, T. W., McKay, R. R., Bilen, M. A., Srinivas, S., Burgess, E. F., Ramamurthy, C., George, S., Geynisman, D. M., Bracarda, S., Borchiellini, D., Geoffrois, L., Maroto Rey, J. P., …, & Rosenberg, J. E. (2023). Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer. Journal of Clinical Oncology, 41(25), 4107-4117. https://doi.org/10.1200/jco.22.02887
Vancouver
O'Donnell PH, Milowsky MI, Petrylak DP, Hoimes CJ, Flaig TW, Mar N, et al. Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer. Journal of Clinical Oncology. 2023;41(25):4107-4117. doi:10.1200/jco.22.02887
BibTeX
@article{ODonnell2023,
author = {O'Donnell, Peter H and Milowsky, Matthew I and Petrylak, Daniel P and Hoimes, Christopher J and Flaig, Thomas W and Mar, Nataliya and Moon, Helen H and Friedlander, Terence W and McKay, Rana R and Bilen, Mehmet A and Srinivas, Sandy and Burgess, Earle F and Ramamurthy, Chethan and George, Saby and Geynisman, Daniel M and Bracarda, Sergio and Borchiellini, Delphine and Geoffrois, Lionnel and Maroto Rey, Jose Pablo and Ferrario, Christiano and Carret, Anne-Sophie and Yu, Yao and Guseva, Maria and Homet Moreno, Blanca and Rosenberg, Jonathan E},
title = {Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer},
journal = {Journal of Clinical Oncology},
year = {2023},
volume = {41},
number = {25},
pages = {4107--4117},
doi = {10.1200/jco.22.02887}
}
EUVIMED